IDEX BIOMETRICS ASA
Reference is made to the notices on 3 March and 10 March 2021 regarding issue of shares to employees under the employee share purchase plan and to employees exercising incentive subscription rights.
The capital increase has been registered and the shares issued. The company's share capital is now NOK 137,508,072.75 divided into 916,720,485 shares each with a nominal value of NOK 0.15.
For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 918 00186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
Brett L Perry, Shelton Group
E-mail: bperry@sheltongroup.com
Tel: + 1 214 272 0070
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
DBV Technologies S.A.17.1.2026 00:11:29 CET | Press release
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Scandinavian Investment Group A/S16.1.2026 22:01:00 CET | Pressemeddelelse
Storaktionærmeddelelse
Scandinavian Investment Group A/S16.1.2026 22:00:00 CET | Pressemeddelelse
Ledende medarbejders transaktion
Tiziana Life Sciences Ltd.16.1.2026 20:45:30 CET | Press release
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Genmab A/S16.1.2026 19:30:00 CET | Press release
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
